There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CXCR4


Brief Information

Name:C-X-C motif chemokine receptor 4
Target Synonym:LCR1,LESTR,LPS-associated protein 3,Leukocyte-Derived Seven Transmembrane Domain Receptor,Stromal Cell-Derived Factor 1 Receptor,Chemokine (C-X-C Motif) Receptor 4,CD184 Antigen,Fusin,FB22,HM89,Seven-Transmembrane-Segment Receptor, Spleen,Chemokine (C-X-C
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:15
Lastest Research Phase:Approved

Product ListCompare or Buy

By Product Status:
By Product Category:
By Species:
By Tag:
By Conjugate:
Cat. No. Species Product Description Structure Purity Feature
CX4-H5269 Human Human CXCR4 / CD184 Protein, Fc Tag

ecule endowed with potent chemotactic activity for lymphocytes. This receptor is one of several chemokine receptors that HIV isolates can use to infect CD4+ T cells. HIV isolates that use CXCR4 are traditionally known as T-cell tropic isolates. Typically, these viruses are found late in infection. It is unclear as to whether the emergence of CXCR4 using HIV is a consequence or a cause of immunodeficiency.CXCR4 is upregulated during the implantation window in natural and hormone replacement therapy cycles in the endometrium, producing, in presence of a human blastocyst, a surface polarization of the CXCR4 receptors suggesting that this receptor is implicated in the adhesion phase of human implantation. SDF-1 and CXCR4 were believed to be a relatively "monogamous" ligand-receptor pair (other chemokines tend to use several different chemokine receptors in a fairly "promiscuous" manner). Recent evidence demonstrates ubiquitin is also a natural ligand of CXCR4. Chronic exposure to THC increased T lymphocyte CXCR4 expression on both CD4+ and CD8+ T lymphocytes. Drugs that block the CXCR4 receptor appear to be capable of "mobilizing" hematopoietic stem cells into the bloodstream as peripheral blood stem cells.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Plerixafor SDZ-SID-791; JM-3100; JKL-169; AMD-3100; PLR-001 Approved Genzyme Corp 释倍灵, Mozobil, Mobozil Mainland China Lymphoma, Non-Hodgkin; Multiple Myeloma Genzyme Europe Bv 2008-12-15 Hematopoietic stem cell transplantation (HSCT); Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hodgkin Disease; Myelodysplastic Syndromes; Kidney Diseases; Multiple Myeloma; Rejection of organ transplantation; Sarcoma, Ewing; Neuroblastoma; Brain Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Lymphoma; Leukemia, Lymphocytic, Chronic, B-Cell Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
JVS-100 JVS-100; SRX-100; ACRX-100; GP-51801; GP51801 Phase 2 Clinical Cleveland Clinic Heart Failure; Ischemia; Peripheral Arterial Disease Details
Ulocuplumab MDX-1338; BMS-936564 Phase 2 Clinical Bristol-Myers Squibb Company Leukemia; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Multiple Myeloma; Lymphoma, Follicular; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details
MSX-122 Q-122; WZ-40; MSX-122 Phase 2 Clinical Altiris Therapeutics Vasomotor symptom; Hot Flashes; Neoplasms Details
NRP-2945 NNZ-4945; NRP-2945 Phase 2 Clinical Neuren Pharmaceuticals Epilepsy Details
X-4136 X-4136 Clinical X4 Pharmaceuticals Lymphoma, B-Cell Details
[68Ga]Pentixafor Phase 1 Clinical The University Of Iowa Neuroendocrine Tumors; Diagnostic agents Details
GMI-1359 GMI-1359 Phase 1 Clinical Glycomimetics Pharmaceutical Breast Neoplasms; Metastatic breast cancer Details
Balixafortide POL-6326 Phase 3 Clinical Polyphor Ltd Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Myeloproliferative Disorders; Multiple Myeloma; Breast Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Lymphocytic, Chronic, B-Cell Details
LY-2510924 T-134; LY-2510924 Phase 2 Clinical Eli Lilly And Company Solid tumours; Carcinoma, Renal Cell; Small Cell Lung Carcinoma Details
PTX-9908 PTX-9908 Phase 2 Clinical Pertinax Therapeutics Liver Neoplasms; Carcinoma, Hepatocellular Details
Mavorixafor X4P-001; X4P-001-RD; X4P-001-LD; ABSK-081; X4P-001-IO; AMD-11070; AMD-070 Phase 3 Clinical Genzyme Corp HIV Infections; Neutropenia; Carcinoma, Renal Cell; Triple Negative Breast Neoplasms; Waldenstrom Macroglobulinemia; Immunologic Deficiency Syndromes; Melanoma Details
Motixafortide BKT-140; BL-8040; TF-14016; TN-14003; 4F-Benzoyl-TN14003 Phase 3 Clinical Biokine Hematopoietic stem cell transplantation (HSCT); Esophageal Neoplasms; Pancreatic Neoplasms; Myelodysplastic Syndromes; Multiple Myeloma; Anemia, Aplastic; Leukemia, Myeloid, Acute; Carcinoma, Non-Small-Cell Lung Details
AD-214 AD-214 Phase 1 Clinical Lung Diseases, Interstitial; Gastroesophageal Reflux Details
USL-311 USL-311 Phase 2 Clinical Ligand Pharmaceuticals Inc Solid tumours; Glioblastoma; Anti-Glomerular Basement Membrane Disease Details

This web search service is supported by Google Inc.